WVEWave Life Sciences Ltd.
$3.47-50% 1Y
$3.47
$3.4752 weeks$21.31
WVE in its own filings
Nothing in WVE's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
266
Events found in the filings · across 737 filings · the record starts in 2015
- Hard flags
- none
Hard flags
- Most recent filing
- Aug 10, 2026
Most recent filing · Form 15-12G
- Record starts
- Oct 2, 2015
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 9, 2026
- SEC comment-letter activity17 occurrences
- 2026-05-05
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Jul 30, 2026Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
- May 18, 2026The information set forth in the press release referred to in.Regulation FD disclosure · Form 8-K
- Apr 28, 2026Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
- Apr 21, 2026Wave Life Sciences Announces Hearing on.Other event · press release
- Apr 15, 2026On April 15, 2026, Wave Life Sciences Ltd., a public company limited by shares incorporated under the laws of the Republic of Singapore (“Wave-Singapore”), announced that it has decided to restructure its corporate group to cause the parent company of the group to be a Delaware corporation (the “Redomiciliation”)Material agreement entered · Form 8-K
- Mar 26, 2026The information set forth in the press release referred to in.Regulation FD disclosure · Form 8-K
- Feb 26, 2026Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update.Earnings release · press release
- Feb 2, 2026Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency.Other event · press release
- Jan 12, 2026Wave Life Sciences Highlights Strategic Priorities for 2026 at the.Earnings release · press release
- Dec 11, 2025On December 9, 2025, Wave Life Sciences Ltd. (the “Company,” “we” or “us”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Leerink Partners LLC and BofA Securities, Inc., as representatives of the several underwriters named therein (the “Underwriters”), relating to the …Material agreement entered · Form 8-K
- Dec 8, 2025The information set forth in the press release referred to in.Regulation FD disclosure · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…